Clinical Trials Search
A Phase 1b Dose-Escalation Study Of TRC105 In Combination With Nivolumab In Patients With Metastatic Non-Small Cell Lung Cancer
The purpose of this research study is to determine the effectiveness and safety of Carotuximab (TRC105) when given in combination with nivolumab (also known as Opdivo®).
Primary: To evaluate safety and tolerability and determine a recommended Phase 2 dose for carotuximab when added to standard dose nivolumab in patients with metastatic NSCLC. Secondary: To assess preliminary evidence of antitumor activity when carotuximab is added to nivolumab, by assessing response rate and progression-free survival. To characterize the pharmacokinetic profile of carotuximab when given with nivolumab. To evaluate the formation of carotuximab anti-product antibodies (APA).